EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Drugs targeting novel pathways in pulmonary arterial hypertension

Olivier Sitbon iD, Athénaïs Boucly iD, Jason Weatherald iD, Fabrice Antigny iD, Christophe Guignabert iD, Mitja Jevnikar, Xavier Jaïs, Laura C Price iD, Martin R Wilkins iD, Roham T Zamanian, Laurent Savale iD, David Montani iD und 1 weitere

European Respiratory Journal · 2025-08 · 66 (2) · 2401830

DOI: 10.1183/13993003.01830-2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 08.05.2025. Verfasst von Olivier Sitbon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France olivier.sitbon@aphp.fr. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Antihypertensive Agents, Hypertension, Pulmonary. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 221 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past three decades, several drugs have been developed to target three major dysfunctional pathways in pulmonary arterial hypertension (PAH), including the prostacyclin, endothelin and nitric oxide pathways. Despite these advances, PAH remains incurable, necessitating further drug discovery efforts. New therapies focus on previously untargeted pathways, especially the bone morphogenetic protein (BMP)/transforming growth factor (TGF)-β signalling pathway. Dysregulation of this pathway, involving the Smad2/3 and Smad1/5/8 signalling branches, plays a key role in pulmonary vascular remodelling. Sotatercept, a fusion protein acting as an activin receptor ligand trap to rebalance growth-promoting and growth-inhibiting signalling has shown promise in clinical trials by reducing pulmonary vascular resistance, improving exercise capacity and lowering risk of a composite of morbi-mortality events. Other emerging treatments aim to restore balance within the BMP/TGF-β pathway. Therapies targeting receptor tyrosine kinases (RTKs), such as imatinib, inhibit the platelet-derived growth factor pathway. Though oral imatinib has shown efficacy, its side-effects have limited widespread use. Additional strategies exploring lower doses of imatinib and novel delivery methods, such as inhalation, to reduce systemic side-effects failed to demonstrate clinical benefit. Novel RTK inhibitors such as seralutinib administered by inhalation have shown promising results in a phase 2 clinical trial. Other emerging approaches include anti-inflammatory therapies, hormonal modulation and metabolism-targeting agents like ranolazine and sodium–glucose cotransporter 2 inhibitors, which could expand the therapeutic landscape for PAH. Overall, the continued development of novel drugs targeting these pathways offers hope for better disease management and improved outcomes for patients with PAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Arterial HypertensionAntihypertensive AgentsHypertension, PulmonaryHumansSignal TransductionTransforming Growth Factor betaBone Morphogenetic ProteinsImatinib MesylateVascular Remodeling

Substanzen

Transforming Growth Factor betaAntihypertensive AgentsBone Morphogenetic ProteinsImatinib Mesylate

Autor:innen und Institutionen

  • Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France olivier.sitbon@aphp.fr.
  • APHP, Hôpital Bicêtre, Service de Pneumologie, Le Kremlin-Bicêtre, France.
  • INSERM, UMR_S999 "Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique", Le Kremlin-Bicêtre, France.
  • Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
  • Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada.
  • National Pulmonary Hypertension Service, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.

ORCID-Profile: Olivier Sitbon, Athénaïs Boucly, Jason Weatherald, Fabrice Antigny, Christophe Guignabert, Laura C Price, Martin R Wilkins, Laurent Savale, David Montani, Marc Humbert

Zitieren

APA

Sitbon, O., Boucly, A., Weatherald, J., Antigny, F., Guignabert, C., Jevnikar, M., Jaïs, X., Price, L. C., Wilkins, M. R., Zamanian, R. T., Savale, L., Montani, D., & Humbert, M. (2025). Drugs targeting novel pathways in pulmonary arterial hypertension. European Respiratory Journal, 66(2), 2401830. https://doi.org/10.1183/13993003.01830-2024

Vancouver

Sitbon O, Boucly A, Weatherald J, Antigny F, Guignabert C, Jevnikar M, et al. Drugs targeting novel pathways in pulmonary arterial hypertension. European Respiratory Journal. 2025;66(2):2401830. doi:10.1183/13993003.01830-2024

BibTeX
@article{Sitbon2025,
  author = {Sitbon, Olivier and Boucly, Athénaïs and Weatherald, Jason and Antigny, Fabrice and Guignabert, Christophe and Jevnikar, Mitja and Jaïs, Xavier and Price, Laura C and Wilkins, Martin R and Zamanian, Roham T and Savale, Laurent and Montani, David and Humbert, Marc},
  title = {Drugs targeting novel pathways in pulmonary arterial hypertension},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {66},
  number = {2},
  pages = {2401830},
  doi = {10.1183/13993003.01830-2024}
}
Kostenlos starten →